Modeling the Cost-Effectiveness of Express Multisite Gonorrhea Screening Among Men Who Have Sex With Men in the United States
Earnest R, Rönn MM, Bellerose M, Menon-Johansson AS, Berruti AA, Chesson HW, Gift TL, Hsu KK, Testa C, Zhu L, Malyuta Y, Menzies NA, Salomon JA. Modeling the Cost-Effectiveness of Express Multisite Gonorrhea Screening Among Men Who Have Sex With Men in the United States. Sexually Transmitted Diseases 2021, 48: 805-812. PMID: 33993161, PMCID: PMC8505150, DOI: 10.1097/olq.0000000000001467.Peer-Reviewed Original ResearchMeSH KeywordsChlamydia InfectionsCost-Benefit AnalysisGonorrheaHomosexuality, MaleHumansMaleMass ScreeningPrevalenceSexual and Gender MinoritiesUnited StatesConceptsGonococcal infectionAsymptomatic MSMAnatomic sitesUS MSMIncremental cost-effectiveness ratioMore anatomic sitesCost-effectiveness ratioExtragenital screeningGonorrhea ScreeningPhysical examinationSmall cost savingsAsymptomatic screeningProvider consultationRoutine screeningMore infectionsOnward transmissionVisit costsCumulative health effectsIntervention yearInfectionMSMHealth effectsDiagnostic costsCost-effective optionMen